Myths vs. Facts Understanding IP, Medical Innovation and Drug Affordability

Drug affordability continues to draw attention from policymakers, patients, employers and advocates – with intellectual property (IP) increasingly at the center of the debate.

A recent Senate Judiciary hearing, Medicines and IP: Balancing Innovation and Access, brought critical attention to the ongoing debate. During the hearing, Ranking Member Hank Johnson (D-GA) spoke to the importance of patents: "Our nation's founders understood that when inventors are rewarded for their contributions, economic growth and human progress follow. More than two centuries later, the success of that vision is self-evident.”

Because of the lengthy development timelines and expense of pharmaceutical research, patents are critical IP protections that support drug development. When an innovator invests in discovering and developing a new drug, two types of IP protections give time to recover that investment and earn a profit: patent protection and data exclusivity. 

Patent protection rewards inventors for sharing how their invention works. Data exclusivity protects the clinical trial results they used to get FDA approval. Both expire after a set period of time. After that time, generic or biosimilar versions can enter the market and fuel competition that helps lower costs.

Four common IP misconceptions are examined below.

Myth: Patents are the main barrier to affordable medicines.

Fact: Patents are fundamental to how new medicines are developed. Bringing a new drug to market can cost more than $2 billion when accounting for failed research and capital costs, and IP provides the temporary certainty that encourages innovators to invest in drug development despite the high risk of failure. The reality is that most modern medicines are built on multiple, distinct innovations – each requiring its own patent protection. These innovations span active ingredients, specialized manufacturing processes, and unique delivery devices that collectively make treatments safer and more accessible. Once any protections expire, generic or biosimilar competition quickly follows. Today, generics account for 90% of U.S. prescriptions. In 2024, generics and biosimilars saved patients and the healthcare system $467 billion. Those savings were only possible because IP protections facilitated the new medicines that were developed first.

Myth: We can have the same innovation and access with price controls. 

Fact: Policies like international reference pricing or Most Favored Nation pricing may appear to offer quick savings, but the evidence points to real downstream consequences that affect access and innovation. One analysis found that these reductions could translate to an average 82% decline in U.S. top-line sales and a 53% drop in global top-line revenue for the drugs analyzed, with MFN-based pricing across 12 high-revenue drugs producing a fall from $97 billion in global sales to just $47 billion. When revenue declines at that scale, the economics of drug development shift – capital moves away from high-risk programs, and entire therapy areas become harder to justify. Price controls that compress revenue do not just reduce margins – they quietly determine which diseases are worth pursuing and which are not. With one in two American adults living with at least one chronic condition, medical advances are needed to lower the burden of illness. 

Myth: Innovation will continue regardless of disruptive policy changes.

Fact: Medical innovation is driven by incentives, which means investment decisions inevitably change when policy changes add risk and uncertainty by, for example, altering the expected return on developing new treatments. The impact of the Inflation Reduction Act is already beginning to show across the drug development pipeline. Following its passage, industry-sponsored post-approval clinical trials declined by 38.4% overall. Investment patterns have shifted as well: funding for small-molecule drugs has fallen 70% since the IRA’s pricing provisions were first proposed, while biologics received ten times more funding than small molecules during the first seven months of 2024. These are not projections: they are early readings of a pipeline already being reshaped by policy, and an indication of which future treatments may never reach patients at all.

Myth: Innovation and affordability are competing goals.

Fact: Innovation and affordability are deeply connected because the same system that produces breakthrough therapies also creates the competition that expands access over time. Many modern treatments have replaced more complex and costly care with simpler options like a daily pill, reducing overall healthcare costs beyond the price of the drug itself. Pricing should reflect the value a treatment delivers while still rewarding innovation and supporting continued research, a balance that blunt price controls can disrupt. The goal is not to choose between the two, but to design policies that reflect value, encourage competition, improve transparency and preserve the incentives needed to bring future therapies to patients.

Drug access and affordability for patients are essential for health, and the pressure on policymakers to act is real. Innovation plays a critical role in addressing unmet needs and stimulating competition, both of which help broaden patient access to therapies over time.

Lasting solutions depend on policies and a system where patients benefit from the treatments available today – and the breakthroughs still to come.

Learn more on the importance of intellectual property protections here: https://www.weworkforhealth.org/ip